2D/3D EX vivo Assays: A PDX-based platform for ex vivo evaluating/screening novel anti-cancer compoundsIMODI Cancer
Oncomedics has developed the Oncogramme®, based on primary culture of cells from human tumor tissues
. It creates a functional profile of a patient tumor’s sensitivity and resistance to various drugs/drug candidates and combinations to provide physicians with the most accurate information for treating a patient’s cancer.
Functional assays are also useful at preclinical stages of drug candidates’ development. Oncomedics has thus developed OncoTRIP™
(Tumor Response Index & Profiling), a exclusive, centralized ex vivo platform for profiling of new agents on tumor-derived primary cultures.
We offer an array of testing services centered on cells from patient-derived tumor xenografts (PDXs). A unique collection of highly characterized PDX cancer models is integrated and available through Oncodesign’s X-Mice® platform
. Specific tumor profiles can therefore be selected for phenotypic exploration (2D/3D models; spheroids) with OncoTRIP™, which is ideally designed and positioned for:
- profiling and qualification of drug candidates;
- selection of relevant tumor models for further in vivo testing.
OncoTRIP™ is an enabling tool bridging advances made in primary cell culture with hard-to-collect, -grow and -investigate patient-derived solid tumor cells. We assist biotechnology and pharmaceutical companies to improve drug candidate validation and reduce time to market.
2D primary culture from non-small cell lung cancer PDX in Oncomedics’ proprietary defined medium
2D primary culture from breast cancer PDX in Oncomedics’ proprietary defined medium, showing emergence of spheroids